FDA Commissioner says every day at FDA is fun, but decision to remain will be made by the next president.
Robert Califf does not appear to be actively packing his desk at FDA's White Oak headquarters as the presidential election nears. He maintains that he would like to continue as FDA commissioner even in the face of potential opposition from both candidates.
Califf, who has been in office less than a year, said Nov. 4 after a speech and discussion at the...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
